Sorafenib promotes hepatocellular carcinoma invasion via interleukin-6/HIF-1α/PFKFB3

Background: Although sorafenib is adopted as the first-line treatment for unresectable liver cancer, the antitumor efficacy is severely limited by the pro-invasive side effect. Methods: To explore the underlying mechanisms, various-dosage sorafenib was applied to survey its effect on cell invasion i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Pengyuan, Wang, Dong, Zhang, Kewei, Wang, Jiandong, Shen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355201/
https://www.ncbi.nlm.nih.gov/pubmed/37476196
http://dx.doi.org/10.7150/jca.84451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355201/
https://www.ncbi.nlm.nih.gov/pubmed/37476196
http://dx.doi.org/10.7150/jca.84451

Ejemplares similares